Grant RDF

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31
• 32
• 33
• 34
• 35
• 36
• 37
• 38
• 39
• 40
• more...

• Age-Related Changes in Optic Nerve Head Structure and Biomechanics
• Age-Related Macular Degeneration: The Effect of Training on Visual Performance and Neural Activity
• Agile and Fused Vehicle Dynamics for Open Architecture and Cyber-Physics System Design
• Agile Tire Mobility for Severe Terrain and Cyber-Threat Environments
• Aging and ARM: Dark Adaptation Impairment
• Aging and Somatotropic Axis and Abeta Toxicity
• Agreement Between ADPH & Bd of Trustees of the Univ of AL for the Univ of AL "TB Contract"
• Agreement Between ADPH & Bd of Trustees of the Univ of AL for the Univ of AL "TB Contract"
• Agreement Between ADPH & The Board of Trustees of the University of AL for the University of Alabama at Birmingham "TB Contract"
• Agreement Between the ADPH and Board of Trustees of the Univ of AL for the Univ of AL at B'ham "TB Contract"
• Agreement Between the ADPH and Board of Trustees of the Univ of AL for the Univ of AL at B'ham "TB Contract"
• Agreement Between The ADPH and The Board of Trustees of the Univ of AL for the Univ of AL at B'ham
• AHA-Data Grant Fellowship
• AHEC Point of Service Maint & Enhancement
• AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
• AHOD1331-A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents
• AHOD1721, Risk-based, Response-Adapted, Phase ll Open- Label Trail of Nivolumab+Brentuximab Vedotin(N+Bv) for Children,Adolescents, and Young Adults with Relapsed/ Refractory (R/R) CD30+ Classic Hodgkin Lymphoma (cHL) after Failure of First -Line Therapy, followed by Brentuximab+Bendamustine(Bv+B) for participants with a suboptimal response;CheckMate 744:Checkpoint Pathway and Nivolumab Clinical Trail Evaluation.
• AIACC Needs Assessment
• AIDS Clinical Trial Group (ACTG 5324) -- A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV
• Aids Clinical Trial Group: ACTG
• Aids Clinical Trials Group (ACTG) - TSG/Research Science Committee
• AIDS Clinical Trials Group (ACTG) A5332/A5340 Salary Support
• AIDS Clinical Trials Group Network (ACTG)
• AIDS Clinical Trials Group: Protocol Funds
• AIDS Clinical Trials Group: Protocol Funds FTE Funding
• AIDS Education & Training Centers Florida/Caribbean AIDS Education and Training Center (AETC)
• AIDS Education and Training Centers Program
• Airways Clinical Research Center (ACRC)
• Airways Clinical Research Centers (ACRC)
• Airways Clinical Research Centers (ACRC) Network

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31
• 32
• 33
• 34
• 35
• 36
• 37
• 38
• 39
• 40
• more...